Abstract. Patients with 22q11.2 deletion syndrome have characteristic facial appearance, palate abnormalities, hypoparathyroidism, thymic hypoplasia, and congenital heart disease. The 22q11.2 region includes TBX1 and 30 other genes. Analysis of Tbx1 transgenic mice showed that TBX1 was associated with the 22q11.2 deletion syndrome. In humans, TBX1 mutations have been reported in 22q11.2 deletion-negative patients with velocardiofacial syndrome or DiGeorge syndrome. Genotypephenotype correlations are not fully understood in these patients. We report the case of an infant with a novel heterozygous TBX1 mutation who experienced hypocalcemic seizures. This patient had no palate abnormalities, cardiac anomalies, or the typical facial appearance observed in 22q11.2 deletion syndrome. The presence of thymic hypoplasia prompted us to perform G-banding, fluorescent in situ hybridization, and subsequent TBX1 analysis. We emphasize the importance of diagnosing thymic hypoplasia in hypocalcemic infants without 22q11.2 deletion for detecting TBX1 mutations.
Introduction
The 22q11.2 deletion syndrome is a multiple gene deletion syndrome characterized by congenital heart disease, palate abnormalities such as cleft palate, sub-mucous cleft palate, and velopharyngeal insufficiency, hypoparathyroidism, immunodeficiency derived from thymus hypoplasia, and distinctive facial features (1) . DiGeorge syndrome (OMIM: 188400), velocardiofacial syndrome (OMIM: 192430), and some cases of conotruncal anomaly face syndrome (OMIM: 217095) are also associated with this syndrome.
The 22q11.2 region covers approximately 30 genes, including TBX1, which was shown to be causative agent of the 22q11.2 deletion syndrome in Tbx1 transgenic mice (2) (3) (4) . TBX1 encodes a transcription factor that regulates organogenesis. Three isoforms of the TBX1 mRNA (TBX1A, TBX1B, and TBX1C) have been; although all three isoforms contain exons 1-8, they differ in the incorporation of subsequent exons, namely, exons 9A, 9B/10, and 9C (5) . Of the three isoforms, TBX1C is the main transcript in humans. TBX1 mutations were previously identified in patients with clinically diagnosed 22q11.2 deletion syndrome in whom deletion of the entire 22q11.2 region was not detected (5) (6) (7) (8) (9) . However, the genotype-phenotype correlations have not yet been completely understood as only 10 TBX1 mutations have been reported to date (8) .
Here, we report the case of an infant with a novel heterozygous TBX1 mutation who experienced hypocalcemic seizures from the neonatal period.
Case Presentation
A 2-mo-old boy was referred to the pediatric neurological department of Okayama University hospital because of repetitive seizures that started at 1 mo of age. He was born by vaginal delivery at 38 wk and 4 d and was the second child of non-consanguineous parents. His birth weight was 2,895 g (−0.48 SD), and he was solely breast-fed. Physiological examination at birth showed no abnormalities except for postaxial polydactyly of the right fifth toe (Fig.  1) . His family history revealed that his uncle experienced febrile seizures during childhood (Fig. 2) . The younger brother of his paternal grandfather also experienced seizures, although the etiology was unclear. There was no family history of polydactyly, congenital heart disease, and hypocalcemia.
At 1 mo of age, recurrent afebrile clonic left hand seizures were observed. Physiological examination did not reveal any new abnormalities, and palate abnormalities and characteristic facial features associated with the 22q11.2 deletion syndrome were not observed. Moreover, no abnormalities were detected by cerebrospinal fluid testing, head computed tomography, echocardiography, or electroencephalogram. Biochemical examination on admission (Table  1) plasma PTH level was found to be normal (42 pg/ ml) despite the hypocalcemia, suggesting that the patient had hypoparathyroidism. Radiological examination revealed thymic hypoplasia (Fig. 3) , which is indicative of 22q11.2 deletion syndrome combined with hypoparathyroidism. No deletion of 22q11.2 was detected by G-banding and fluorescent in situ hybridization analysis. The development and growth of the patient is normal at 9 yr of age, and no seizures have been observed since the correction of hypocalcemia.
His facial appearance is also normal. The dosage of oral alfacalcidol has been increased to 1.0 µg/d from 0.25 µg/d at 2 mo of age because mild hypocalcemia was detected during his growth.
We obtained informed consent from his parents to conduct TBX1 analysis. Genomic DNA from peripheral leukocytes was extracted using the QIAamp DNA blood mini kit (Qiagen Inc., Tokyo, Japan). The genetic analysis was approved by the ethical committee of the Okayama University Hospital. All exons and exon-intron boundaries of TBX1 (accession number: NC_000022.11) were amplified using standard polymerase chain reaction (PCR). Primer sequences are available on demand. Amplified products were purified by the QIAquick PCR purification kit (Qiagen Inc.) and sequenced using the BigDye® Terminator v3.1 cycle sequencing kit and the ABI Prism 310 genetic analyzer (Applied Biosystems, Foster City, CA, USA). Next, the amplicon was cloned into PCR ® 4-TOPO ® vector using the TOPO ® TA cloning kit for sequencing (Thermo Fisher Scientific, Inc., Waltham, MA, USA) and each transformant was sequenced. As a result, we identified a frameshift mutation caused by the heterozygous duplication of 11 bases (c.967_977dupAACCCCGTGGC) in exon 8 (Fig. 4A) isoforms of the TBX1 mRNA (Fig. 4B) . Familial analysis was not performed because his parents were divorced. Therefore, we could not determine whether this mutation was de novo or inherited from his parents.
Discussion
We identified a novel heterozygous TBX1 mutation in a 2-mo-old boy with hypocalcemic seizures. To our knowledge, this is the second youngest patient in whom a TBX1 mutation has been identified (8) .
Tbx1 is a key gene involved in the development of the normal parathyroid gland, and abnormal Tbx1 mRNA expression has been shown to cause hypoparathyroidism in Tbx1 transgenic or knockout mice (10) . Here, we report that thymic hypoplasia is also caused by dosage change of Tbx1. On the contrary, thymic hypoplasia is not reported in patients with CRKL and MAPK1 deletions and in heterozygous or homozygous Crkl knock out mouse (11) (12) (13) . Furthermore, chromosomal analysis and FISH did not identify 22q11.2 deletion in our patient. Therefore, we analyzed TBX1 for the presence of mutations.
Both gain-of-function and loss-of-function mutations were reported in patients with clinical features of the 22q11.2 deletion syndrome (7). Increased or decreased dose of Tbx1 in mouse leads to hypoplasia of the thymus and parathyroid glands, which is also observed in human patients with the 22q11.2 deletion syndrome (10) . The TBX1 mutation identified in our case is predicted to cause premature termination of all TBX1 mRNA isoforms, although we could not determine whether this mutation causes nonsense-mediated RNA decay. Further experiments are required to clarify the pathogenicity of this mutation in our patient.
We initially suspected vitamin D-deficient hypocalcemia because his serum 25(OH) vitamin D levels were low and other symptoms suggestive of 22q11.2 deletion syndrome, such as cardiac anomaly, palate abnormalities, and characteristic facial features, were not observed except for postaxial polydactyly of the toe which is observed occasionally among patients with 22q11.2 deletion (14) . Thymic hypoplasia identified by radiological examination was the key finding that prompted us to consider the 22q11.2 deletion syndrome, and to conduct chromosomal analysis and subsequent TBX1 analysis in this patient. A previous study of TBX1 mutation-positive patients showed that all the phenotypes of the 22q11.2 deletion syndrome are not present in patients, resulting in the absence of a genotype-phenotype correlation (8) . These results indicate the existence of a broad spectrum of phenotypes of patients with TBX1 mutations, ranging from all symptoms observed in cases with the 22q11.2 deletion syndrome, such as cardiac anomaly, thymic hypoplasia, palate abnormalities, characteristic facial features, and hypoparathyroidism, to combinations of some of these symptoms as observed in our patient and in previously reported cases (5-9).
In conclusion, we identified a novel heterozygous TBX1 mutation that resulted in hypoparathyroidism and thymic hypoplasia in our patient. We propose that 22q11.2 deletionnegative neonates and infants, who present with only hypoparathyroidism, should be examined for thymic hypoplasia, which might lead to the detection of TBX1 mutations.
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